Liang Juan, Gao Yan, Nan Lianghuan, Zhao Jinli, Zhao Yan, Wei Ruihua
Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, China.
Taiyuan Aier Eye Hospital, Taiyuan, China.
Ophthalmol Ther. 2025 Sep;14(9):2301-2312. doi: 10.1007/s40123-025-01218-8. Epub 2025 Jul 29.
In recent years, the continuous rise in diabetes prevalence has led to a significant increase in the number of patients with diabetic cataracts. Femtosecond laser-assisted cataract surgery (FLACS), as an innovative technology in the field of cataract treatment, has demonstrated remarkable advantages over conventional phacoemulsification (CPS) in terms of surgical precision and efficiency. However, the unique ocular pathological changes in patients with diabetes (such as fragile lens capsules, posterior synechiae of the iris, and increased risk of postoperative inflammatory reactions) pose distinct challenges for cataract surgery. Currently, there is a lack of evidence-based medical data regarding the safety and efficacy of FLACS in this specific population.
In this prospective study, 87 patients with diabetic cataract were randomized to the CPS (n = 46) and FLACS group (n = 41). Baseline characteristics and postoperative outcomes (central macular thickness [CMT], corneal thickness [CT], best-corrected visual acuity [BCVA], aqueous prostaglandin E2 [PGE2]) were analyzed. A non-diabetic control group (n = 40) underwent identical evaluations, including pupil size measurement.
Baseline characteristics showed no significant differences between groups (p > 0.05). FLACS and CPS groups demonstrated comparable CMT and CT at all time points (preoperative, 1 week, 1 month, 3 months), although both groups showed increased values postoperatively versus baseline (p < 0.05). The FLACS group achieved significantly better BCVA at 1-day postoperative assessment (p < 0.05) and exhibited higher aqueous PGE2 levels (p < 0.05). Patients with diabetic cataract and non-diabetic cataract had similar anatomical and visual outcomes (p > 0.05), but diabetics maintained higher postoperative PGE2 levels following FLACS (p < 0.05). No significant difference in pupil diameter was observed between the two groups (p > 0.05).
FLACS showed comparable safety to CPS with faster visual recovery but higher PGE2 in patients with diabetic cataract, requiring close postoperative monitoring.
近年来,糖尿病患病率持续上升,导致糖尿病性白内障患者数量显著增加。飞秒激光辅助白内障手术(FLACS)作为白内障治疗领域的一项创新技术,在手术精度和效率方面比传统超声乳化白内障吸除术(CPS)具有显著优势。然而,糖尿病患者独特的眼部病理变化(如晶状体囊膜脆弱、虹膜后粘连以及术后炎症反应风险增加)给白内障手术带来了独特的挑战。目前,缺乏关于FLACS在这一特定人群中的安全性和有效性的循证医学数据。
在这项前瞻性研究中,87例糖尿病性白内障患者被随机分为CPS组(n = 46)和FLACS组(n = 41)。分析基线特征和术后结果(中心黄斑厚度[CMT]、角膜厚度[CT]、最佳矫正视力[BCVA]、房水前列腺素E2[PGE2])。一个非糖尿病对照组(n = 40)接受了相同的评估,包括瞳孔大小测量。
基线特征在各组之间无显著差异(p > 0.05)。FLACS组和CPS组在所有时间点(术前、1周、1个月、3个月)的CMT和CT相当,尽管两组术后的值均高于基线(p < 0.05)。FLACS组在术后1天评估时BCVA显著更好(p < 0.05),并且房水PGE2水平更高(p < 0.05)。糖尿病性白内障患者和非糖尿病性白内障患者具有相似的解剖和视觉结果(p > 0.05),但糖尿病患者在接受FLACS后术后PGE2水平更高(p < 0.05)。两组之间瞳孔直径无显著差异(p > 0.05)。
在糖尿病性白内障患者中,FLACS与CPS安全性相当,视觉恢复更快,但PGE2水平更高,术后需要密切监测。